Market Overview

DarioHealth: Q2 Earnings Insights

Share:

Shares of DarioHealth (NASDAQ:DRIO) moved higher by 2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 423.08% year over year to ($0.68), which beat the estimate of ($1.40).

Revenue of $1,787,000 up by 8.24% from the same period last year, which beat the estimate of $1,550,000.

Outlook

DarioHealth hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 12, 2020

Time: 09:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2224/36466

Technicals

52-week high: $18.84

52-week low: $0.20

Price action over last quarter: Up 123.19%

Company Profile

DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.

 

Related Articles (DRIO)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com